Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Earnings Data
Report Date
Mar 11, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.11Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented significant growth in Rolvedon sales and market share, alongside strategic product advancements, contributing to a strong financial position. However, challenges such as the decline in Indocin sales due to generic competition and temporary cash flow impacts from sales pull-forwards were noted, alongside costs related to the decommercialization of Otrexup.Company Guidance
Rolvedon Sales Surge
Rolvedon net product sales were $38.6 million for the third quarter of 2025, up from $15 million in the prior year quarter due to the pull-forward of 2 quarters of sales. This contributed to an adjusted EBITDA of $20.9 million, up from $4.4 million in the prior year quarter.
Sympazan Sales Growth
Sympazan net product sales grew to $2.8 million for the third quarter of 2025, up from $2.6 million in the prior year quarter, driven by higher volume.
Strong Financial Position
GAAP net income for the third quarter was $11.4 million compared to a loss of $3 million in the prior year. Cash, cash equivalents, and short-term investments totaled $93.4 million as of September 30, 2025.
Market Share and Demand Growth
Assertio achieved a 43% market share in the clinic Medicare Part B segment for Rolvedon in the third quarter, with a 42% year-to-date demand growth compared to the same period in 2024.
ASRT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ASRT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 10, 2025 | $0.80 | $0.92 | +15.00% |
Aug 11, 2025 | $0.72 | $0.82 | +13.89% |
May 12, 2025 | $0.62 | $0.61 | -1.61% |
Mar 12, 2025 | $0.78 | $0.72 | -7.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Assertio Therapeutics Inc (ASRT) report earnings?
Assertio Therapeutics Inc (ASRT) is schdueled to report earning on Mar 11, 2026, Before Open (Confirmed).
What is Assertio Therapeutics Inc (ASRT) earnings time?
Assertio Therapeutics Inc (ASRT) earnings time is at Mar 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASRT EPS forecast?
ASRT EPS forecast for the fiscal quarter 2025 (Q4) is -0.21.